Clara Locher
@claralocher.bsky.social
PH en pharmacologie clinique 💊 🏥 @CHURennes. COI : RAS. N4 🐠🐡. Mi-pro|Mi-perso|Mi-allegretto.
Art divinatoire et médecine douce… s’il fallait une preuve que la médecine douce, c’est de l’ésotérisme 😅
October 11, 2025 at 5:58 PM
Art divinatoire et médecine douce… s’il fallait une preuve que la médecine douce, c’est de l’ésotérisme 😅
◀️ cherche façon digne de descendre un escalier après un semi.
#J2desCourbat
#J2desCourbat
September 2, 2025 at 3:40 PM
◀️ cherche façon digne de descendre un escalier après un semi.
#J2desCourbat
#J2desCourbat
Reposted by Clara Locher
🗨️ “There is clearly a crisis in research integrity that needs urgent action by all involved.”
A new Comment introduces The Lancet–@wcrifoundation.bsky.social Commission on Research Integrity. Read now: tinyurl.com/3psuemmz
A new Comment introduces The Lancet–@wcrifoundation.bsky.social Commission on Research Integrity. Read now: tinyurl.com/3psuemmz
The Lancet–World Conferences on Research Integrity Foundation Commission on Research Integrity
Progress in clinical medicine and public health to improve people's lives is based
on research findings that should be relevant and trustworthy. However, around 3% of
recent biomedical articles are fa...
tinyurl.com
August 5, 2025 at 8:53 AM
🗨️ “There is clearly a crisis in research integrity that needs urgent action by all involved.”
A new Comment introduces The Lancet–@wcrifoundation.bsky.social Commission on Research Integrity. Read now: tinyurl.com/3psuemmz
A new Comment introduces The Lancet–@wcrifoundation.bsky.social Commission on Research Integrity. Read now: tinyurl.com/3psuemmz
Les filles sur le chemin de retour de la plage arrachent de fleurs de laurier rose.
Je les gronde gentiment en disant que c’est plus joli sur l’arbre et elles me répondent mais on les mange et c’est bon 😭😭😭😭😭
Je les gronde gentiment en disant que c’est plus joli sur l’arbre et elles me répondent mais on les mange et c’est bon 😭😭😭😭😭
July 16, 2025 at 7:48 PM
Les filles sur le chemin de retour de la plage arrachent de fleurs de laurier rose.
Je les gronde gentiment en disant que c’est plus joli sur l’arbre et elles me répondent mais on les mange et c’est bon 😭😭😭😭😭
Je les gronde gentiment en disant que c’est plus joli sur l’arbre et elles me répondent mais on les mange et c’est bon 😭😭😭😭😭
Direction un concert choisi par @totomathon.bsky.social
Ceux qui savent, savent.
PS : faut-il passer un audiogramme avant | après ?
Ceux qui savent, savent.
PS : faut-il passer un audiogramme avant | après ?
a poster for metal horde with a skull and skeleton hands
ALT: a poster for metal horde with a skull and skeleton hands
media.tenor.com
June 20, 2025 at 4:30 PM
Direction un concert choisi par @totomathon.bsky.social
Ceux qui savent, savent.
PS : faut-il passer un audiogramme avant | après ?
Ceux qui savent, savent.
PS : faut-il passer un audiogramme avant | après ?
« Although phase 3 trials are often interpreted as demonstrating superiority, overall survival and quality of life, which may be the most relevant end points to patients, are uncommonly improved. »
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials
This meta-epidemiological study analyzes phase 3 oncology randomized clinical trials to determine the proportions of trials that show improvement in overall survival, quality of life, and alternative ...
jamanetwork.com
June 2, 2025 at 8:20 PM
« Although phase 3 trials are often interpreted as demonstrating superiority, overall survival and quality of life, which may be the most relevant end points to patients, are uncommonly improved. »
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Clara Locher
🎉 Kudos to Giulia @giulia-varvar.bsky.social for her speed talk at "Printemps de la Recherche" last Tuesday! She presented about SHARE-CTD, and her project on re-analysis of pivotal trials in Oncology, to Irset’s 350+ pros. A great moment to showcase open science in medicine!🔬
#SHARECTD #OpenScience
#SHARECTD #OpenScience
May 16, 2025 at 2:13 PM
🎉 Kudos to Giulia @giulia-varvar.bsky.social for her speed talk at "Printemps de la Recherche" last Tuesday! She presented about SHARE-CTD, and her project on re-analysis of pivotal trials in Oncology, to Irset’s 350+ pros. A great moment to showcase open science in medicine!🔬
#SHARECTD #OpenScience
#SHARECTD #OpenScience
Reposted by Clara Locher
Éh les gars il reste 24h pour recueillir 200 000 signatures, on peut le faire si tout le monde dans le monde signe et partage !
eci.ec.europa.eu/043/public/#...
eci.ec.europa.eu/043/public/#...
May 16, 2025 at 6:36 AM
Éh les gars il reste 24h pour recueillir 200 000 signatures, on peut le faire si tout le monde dans le monde signe et partage !
eci.ec.europa.eu/043/public/#...
eci.ec.europa.eu/043/public/#...
📢 SAVE THE DATE
🎓 La Rentrée de la Méthodo revient pour sa 6ᵉ édition !
📍 Lyon
📅 3 septembre 2025
🧠 Une journée, deux thématiques clés :
📊 PROMs [Patient-Reported Outcome Measures]
📈 Analyses de survie
#Méthodo #RechercheClinique #PROMs #Survie
www.sfpt-fr.org/images/docum...
🎓 La Rentrée de la Méthodo revient pour sa 6ᵉ édition !
📍 Lyon
📅 3 septembre 2025
🧠 Une journée, deux thématiques clés :
📊 PROMs [Patient-Reported Outcome Measures]
📈 Analyses de survie
#Méthodo #RechercheClinique #PROMs #Survie
www.sfpt-fr.org/images/docum...
April 24, 2025 at 10:28 AM
📢 SAVE THE DATE
🎓 La Rentrée de la Méthodo revient pour sa 6ᵉ édition !
📍 Lyon
📅 3 septembre 2025
🧠 Une journée, deux thématiques clés :
📊 PROMs [Patient-Reported Outcome Measures]
📈 Analyses de survie
#Méthodo #RechercheClinique #PROMs #Survie
www.sfpt-fr.org/images/docum...
🎓 La Rentrée de la Méthodo revient pour sa 6ᵉ édition !
📍 Lyon
📅 3 septembre 2025
🧠 Une journée, deux thématiques clés :
📊 PROMs [Patient-Reported Outcome Measures]
📈 Analyses de survie
#Méthodo #RechercheClinique #PROMs #Survie
www.sfpt-fr.org/images/docum...
Reposted by Clara Locher
J’ai porté plainte ce matin.
Un site d’extrême droite appelle à ma mise à mort à travers une « Aktion T4 ». ↓
Un site d’extrême droite appelle à ma mise à mort à travers une « Aktion T4 ». ↓
April 5, 2025 at 10:31 AM
J’ai porté plainte ce matin.
Un site d’extrême droite appelle à ma mise à mort à travers une « Aktion T4 ». ↓
Un site d’extrême droite appelle à ma mise à mort à travers une « Aktion T4 ». ↓
Pour changer des concerts, troisième soirée Mythos avec un peu de @ericlagadec.bsky.social dedans ✨🪐⭐️💫
April 5, 2025 at 3:47 PM
Pour changer des concerts, troisième soirée Mythos avec un peu de @ericlagadec.bsky.social dedans ✨🪐⭐️💫
Publishing a paper on éditorial self-publication in a journal where one author is an editor emeritus… 🫢
The circle is complete 🤷🏻♀️
The circle is complete 🤷🏻♀️
April 3, 2025 at 6:47 AM
Publishing a paper on éditorial self-publication in a journal where one author is an editor emeritus… 🫢
The circle is complete 🤷🏻♀️
The circle is complete 🤷🏻♀️
#lecanemab Update as of April 2025
The EC announced that it has deliberated on the MAA in its Standing Committee and, based on the results of those deliberations, has referred the decision to the Appeal Committee in accordance with the EC review process.
The EC announced that it has deliberated on the MAA in its Standing Committee and, based on the results of those deliberations, has referred the decision to the Appeal Committee in accordance with the EC review process.
April 1, 2025 at 3:48 PM
#lecanemab Update as of April 2025
The EC announced that it has deliberated on the MAA in its Standing Committee and, based on the results of those deliberations, has referred the decision to the Appeal Committee in accordance with the EC review process.
The EC announced that it has deliberated on the MAA in its Standing Committee and, based on the results of those deliberations, has referred the decision to the Appeal Committee in accordance with the EC review process.
Update as of february 2025
April 1, 2025 at 3:45 PM
Update as of february 2025
Reposted by Clara Locher
Important ! la date limite de candidatures pour le CA et le CS est repoussée au 14 avril! n'hésitez pas à déposer votre candidature pour participer à la vie de la Société
sfpt-fr.org/vie-de-la-sf...
sfpt-fr.org/vie-de-la-sf...
Deadline candidatures CA et CS repoussée au 14 avril
Société Française de Pharmacologie et de Thérapeutique
sfpt-fr.org
March 28, 2025 at 12:23 PM
Important ! la date limite de candidatures pour le CA et le CS est repoussée au 14 avril! n'hésitez pas à déposer votre candidature pour participer à la vie de la Société
sfpt-fr.org/vie-de-la-sf...
sfpt-fr.org/vie-de-la-sf...
Reposted by Clara Locher
News story on RestoRes's website, following @ioanaacristea.bsky.social findings about a large clinical trial on esketamine for supplemental analgesia in cesarean delivery, published in JAMA Network Open. 👇 👇 👇
restores.univ-rennes.fr/highlights/z...
restores.univ-rennes.fr/highlights/z...
March 28, 2025 at 10:48 AM
News story on RestoRes's website, following @ioanaacristea.bsky.social findings about a large clinical trial on esketamine for supplemental analgesia in cesarean delivery, published in JAMA Network Open. 👇 👇 👇
restores.univ-rennes.fr/highlights/z...
restores.univ-rennes.fr/highlights/z...
Des nouvelles de Joyeux et Fourtillan
March 9, 2025 at 6:11 PM
Des nouvelles de Joyeux et Fourtillan
🔽🔽
February 7, 2025 at 10:18 PM
🔽🔽
Sorry for the photo, but this edito 🫶
American chaos: standing up for health and medicine - The Lancet
www.thelancet.com/journals/lan...
American chaos: standing up for health and medicine - The Lancet
www.thelancet.com/journals/lan...
American chaos: standing up for health and medicine
Withdrawal from WHO and the Paris Agreements. USAID shuttered and aid halted, ceasing
health programmes globally. A freeze on US$3 trillion worth of federal grants and
loans, jeopardising the function...
www.thelancet.com
February 7, 2025 at 10:16 PM
Sorry for the photo, but this edito 🫶
American chaos: standing up for health and medicine - The Lancet
www.thelancet.com/journals/lan...
American chaos: standing up for health and medicine - The Lancet
www.thelancet.com/journals/lan...
Reposted by Clara Locher
The 1st schooling of the SHARE-CTD project took place in person with international principal investigators, partners and doctoral students at Günzburg in Germany from 27.01. to 31.01.2025. Get ready for the next generation of researchers well trained in clinical trial data sharing. www.sharectd.eu
February 3, 2025 at 11:23 AM
The 1st schooling of the SHARE-CTD project took place in person with international principal investigators, partners and doctoral students at Günzburg in Germany from 27.01. to 31.01.2025. Get ready for the next generation of researchers well trained in clinical trial data sharing. www.sharectd.eu
Re-examination of a re-examination procedure…
New twist for lecanemab:
@ec.europa.eu has asked @ema.europa.eu ‘s Committee for Medicinal Products for Human Use to reconsider his (controversial) approval and to examine the latest safety information available on the anti-Alzheimer drug Leqembi (lecanemab). This is very rare. 😵💫 (in French 👇
@ec.europa.eu has asked @ema.europa.eu ‘s Committee for Medicinal Products for Human Use to reconsider his (controversial) approval and to examine the latest safety information available on the anti-Alzheimer drug Leqembi (lecanemab). This is very rare. 😵💫 (in French 👇
APMnews - Le CMUH prié de se repencher sur l'anti-Alzheimer Leqembi*
www.apmnews.com
January 31, 2025 at 6:13 PM
Re-examination of a re-examination procedure…
Reposted by Clara Locher
New twist for lecanemab:
@ec.europa.eu has asked @ema.europa.eu ‘s Committee for Medicinal Products for Human Use to reconsider his (controversial) approval and to examine the latest safety information available on the anti-Alzheimer drug Leqembi (lecanemab). This is very rare. 😵💫 (in French 👇
@ec.europa.eu has asked @ema.europa.eu ‘s Committee for Medicinal Products for Human Use to reconsider his (controversial) approval and to examine the latest safety information available on the anti-Alzheimer drug Leqembi (lecanemab). This is very rare. 😵💫 (in French 👇
APMnews - Le CMUH prié de se repencher sur l'anti-Alzheimer Leqembi*
www.apmnews.com
January 31, 2025 at 5:46 PM
New twist for lecanemab:
@ec.europa.eu has asked @ema.europa.eu ‘s Committee for Medicinal Products for Human Use to reconsider his (controversial) approval and to examine the latest safety information available on the anti-Alzheimer drug Leqembi (lecanemab). This is very rare. 😵💫 (in French 👇
@ec.europa.eu has asked @ema.europa.eu ‘s Committee for Medicinal Products for Human Use to reconsider his (controversial) approval and to examine the latest safety information available on the anti-Alzheimer drug Leqembi (lecanemab). This is very rare. 😵💫 (in French 👇
A small excess of transparency?
January 28, 2025 at 8:47 AM
A small excess of transparency?
Mais, il n’est PAS ÉPIDÉMIOLOGISTE 🤨
Bon, accessoirement, il n’y a rien qui va dans ce qui est décrit dans cet article.
www.mediapart.fr/journal/fran...
Bon, accessoirement, il n’y a rien qui va dans ce qui est décrit dans cet article.
www.mediapart.fr/journal/fran...
January 27, 2025 at 3:29 PM
Mais, il n’est PAS ÉPIDÉMIOLOGISTE 🤨
Bon, accessoirement, il n’y a rien qui va dans ce qui est décrit dans cet article.
www.mediapart.fr/journal/fran...
Bon, accessoirement, il n’y a rien qui va dans ce qui est décrit dans cet article.
www.mediapart.fr/journal/fran...